Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients | Zendy

John R. Wingard | Zendy; William G. Merz | Zendy; Michael G. Rinaldi | Zendy; Carole B. Miller | Zendy; Judith E. Karp | Zendy; Rein Saral | Zendy

Open Access

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

Author(s) -

John R. Wingard,

William G. Merz,

Michael G. Rinaldi,

Carole B. Miller,

Judith E. Karp,

Rein Saral

Publication year - 1993

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.37.9.1847

Subject(s) - fluconazole , candida krusei , candida glabrata , fungemia , medicine , neutropenia , flucytosine , mycosis , amphotericin b , microbiology and biotechnology , biology , surgery , candida albicans , antifungal , chemotherapy

Because the use of fluconazole prophylaxis had been associated with an increased rate of Candida krusei infections at The John Hopkins Oncology Center, early empiric amphotericin B plus flucytosine were given to febrile neutropenic patients colonized by C. krusei. By this practice, the proportion of fungemias attributable to C. krusei was low (12.5%) in patients receiving fluconazole over a 6-month interval. However, Torulopsis (Candida) glabrata assumed a much higher proportion of fungemias (75%) among patients receiving fluconazole. In vitro susceptibility testing combined with this clinical experience suggests that some T. glabrata isolates are not susceptible to fluconazole and can cause breakthrough infections in patients receiving fluconazole.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research